Man Group
ABCL icon

Man Group’s AbCellera Biologics ABCL Stock Holding History

Man Group’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-771,934
Closed -$3.5M – 2002
2024
Q1 		$3.5M Buy
+771,934
New +$3.94M 0.01% 1109
2023
Q1 		– Sell
-305,478
Closed -$3.09M – 2054
2022
Q4 		$3.09M Sell
305,478
-359,944
-54% -$4.16M 0.01% 1010
2022
Q3 		$6.58M Buy
+665,422
New +$7.3M 0.03% 635
2022
Q2 		– Hold
0
– – – 1128
2021
Q4 		– Sell
-49,165
Closed -$985K – 1927
2021
Q3 		$985K Buy
49,165
+3,308
+7% +$58.5K ﹤0.01% 1340
2021
Q2 		$1.01M Buy
45,857
+552
+1% +$15.2K ﹤0.01% 1393
2021
Q1 		$1.54M Buy
+45,305
New +$1.8M 0.01% 1184

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $96.1B AUM 40.06% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FFVM
Founders Fund VII Management San Francisco, California $2.03M AUM 72.34% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Man Group's ABCL Position: Q2 2024 in Review

Man Group sold out of AbCellera Biologics (ABCL) in Q2 2024, closing a stake of 771,934 shares — an estimated $3.5M sold.

Man Group first reported a position in ABCL in Q1 2021 and held it in 6 quarters. The position peaked at $6.58M in Q3 2022. 146 funds tracked by Wall St. Rank hold ABCL as of Q2 2024.

  • Man Group reported no remaining AbCellera Biologics position as of Q2 2024 after selling out during the quarter.
  • Man Group sold 771,934 AbCellera Biologics shares in Q2 2024, an estimated $3.5M.
  • Man Group first reported a position in AbCellera Biologics in Q1 2021 and held it in 6 quarters.
  • Man Group's AbCellera Biologics position peaked at $6.58M in Q3 2022.
  • 146 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2024.

Based on Man Group's 13F filing for Q2 2024, filed 14 Aug 2024.